Influenza Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Vaccine Type, Indication, Age Group, Route of Administration, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Influenza Vaccines Market size was more than USD 9.5 billion in 2026 and is set to grow at a 6.18% CAGR between 2027 and 2036, crossing USD 17.3 billion by 2036. The industry revenue for 2027 is estimated at USD 9.99 billion.

• Base Year Value (2026): USD 9.5 billion
• CAGR (2027-2036): 6.18%
• Forecast Year Value (2036): USD 17.3 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Influenza Vaccines Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America captured 56.02% of the market in 2026, backed by strong immunization infrastructure, established procurement systems, and reliable seasonal vaccination demand through multiple healthcare channels.
  • Asia Pacific is forecast to grow at an 8.02% CAGR, supported by expanding immunization access, broader vaccination outreach, and increasing healthcare participation in preventive seasonal influenza vaccination programs.

• Segment Momentum:

  • Inactivated vaccines accounted for 87.34% of the market in 2026, supported by their established role in immunization programs and well-developed manufacturing, distribution, and administration pathways.
  • Quadrivalent vaccines held an 82.43% share in 2026 and are also the fastest-growing segment, benefiting from broader strain coverage and strong alignment with seasonal vaccination planning requirements.

• Market Expansion Drivers:

  • Rising global influenza incidence strengthening annual vaccination demand across adult populations.
  • Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion.
  • Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness.

• Leading Market Participants:

  Top companies in the influenza vaccines market include Sanofi S.A. (France), GSK plc (United Kingdom), CSL Limited (Australia), AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Seqirus Ltd. (United Kingdom), Moderna, Inc. (United States), Merck & Co., Inc. (United States), Sinovac Biotech Ltd. (China), Viatris Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 9.5 billion
  • 2027 Estimated Market Size: USD 9.99 billion.
  • Projected Market Size: USD 17.3 billion by 2036
  • Growth Forecasts: 6.18% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Inactivated (Vaccine Type) | Quadrivalent (Indication) | Adult (Age Group) | Injection (Route of Administration) | Hospitals & Pharmacies (Distribution Channel)
  • Emerging Opportunity Segment: Live Attenuated (Vaccine Type) | Quadrivalent (Indication) | Pediatric (Age Group) | Nasal Spray (Route of Administration) | Government & Institutional Supply (Distribution Channel)

Market Growth Drivers and Industry Trends

Rising global influenza incidence strengthening annual vaccination demand across adult populations

Rising incidence of influenza is reinforcing the need for recurring immunization, particularly among adult populations exposed to seasonal outbreaks and associated health risks. The influenza vaccines market will benefit from continued demand for annual vaccination as immunity may decline over time and circulating influenza strains can vary between seasons. Greater awareness of preventive healthcare and the importance of vaccination among adults can also encourage more consistent participation in seasonal immunization programs, supporting demand across healthcare delivery channels.

Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion

Government-backed vaccination initiatives and influenza surveillance activities are strengthening public health infrastructure around seasonal disease prevention. Such programs support the influenza vaccines market by improving population awareness, identifying patterns of influenza circulation, and facilitating targeted immunization efforts among groups considered more vulnerable to complications. Coordinated vaccination campaigns can also improve access through public healthcare facilities and community-based programs, while surveillance data helps health authorities plan vaccination activities around evolving seasonal disease patterns.

Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness

Technological progress in vaccine development is creating opportunities to improve how influenza vaccines address changing viral strains and evolving immunization requirements. Advancements in mRNA and combination technologies will propel the influenza vaccines market by enabling researchers to explore more adaptable vaccine platforms and broader protection approaches. These technologies can also support responsive manufacturing strategies, while combination formulations may simplify vaccination by addressing multiple relevant strains or targets within a single product.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global influenza incidence strengthening annual vaccination demand across adult populations	2.00%	High	North America, Europe, Asia Pacific	High	Near Term
Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion	1.80%	High	North America, Europe, Asia Pacific	High	Mid Term
Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness	1.50%	High	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for a 56.02% share of the influenza vaccines market in 2026, supported by established immunization infrastructure, strong public health systems, and broad awareness of seasonal influenza prevention. Demand is reinforced by routine vaccination programs, healthcare-provider recommendations, and the continued emphasis on reducing influenza-related healthcare burdens. Advanced vaccine distribution networks, well-developed clinical capabilities, and strong preparedness for seasonal outbreaks further underpin the region's market position.

Asia Pacific is the fastest-growing region, driven by expanding healthcare access, improving immunization infrastructure, and rising awareness of preventive healthcare. Governments and healthcare providers are placing greater emphasis on vaccination as part of broader infectious disease prevention strategies, encouraging wider access to influenza immunization. Strengthening cold-chain capabilities, growing healthcare investment, and increasing public awareness are supporting broader vaccine adoption across the region.

Key Country Insights

United States

Seasonal Immunization Innovation

The U.S. influenza vaccines market emphasizes broad seasonal immunization programs, expanded manufacturing capacity, and the adoption of advanced vaccine technologies. Healthcare providers and public agencies in the U.S. continue to prioritize reliable supply and improved vaccine effectiveness across diverse population groups.

Japan

Aging Population Protection

Japan prioritizes influenza vaccination strategies that address the needs of its older population while maintaining consistent immunization coverage. The influenza vaccines market in Japan benefits from strong clinical standards and continued evaluation of improved vaccine formulations.

South Korea

Domestic Vaccine Development

South Korea strengthens the influenza vaccines market by investing in local vaccine production and expanding national immunization capabilities. The country increasingly supports innovation that enhances supply resilience and responds efficiently to seasonal vaccination requirements.

Germany

Public Health Procurement Focus

Germany supports the influenza vaccines market through coordinated vaccination campaigns and structured procurement practices. Demand in Germany increasingly reflects interest in high-value vaccine formulations that improve protection for aging populations and high-risk patient groups.

France

Preventive Care Expansion

France continues to strengthen influenza vaccination through preventive healthcare initiatives and broader public awareness efforts. The influenza vaccines market in France benefits from policies encouraging higher vaccination uptake among vulnerable populations and healthcare professionals.

Italy

Regional Vaccination Coordination

Italy focuses on improving influenza vaccine accessibility through regional healthcare systems and coordinated immunization campaigns. The influenza vaccines market in Italy reflects continued attention to protecting elderly populations while maintaining stable vaccine procurement across public health networks.

Segment Leadership and Growth Trends

 

Vaccine Type Segment Analysis: Inactivated (Largest Segment) vs Live Attenuated (Fastest-Growing Segment)

The inactivated segment led the influenza vaccines market, accounting for an 87.34% share in 2026. Its dominant position is supported by widespread use across diverse patient populations and established integration into seasonal immunization programs. Inactivated influenza vaccines are commonly administered through established healthcare settings and benefit from broad acceptance among healthcare providers and public health systems. Ongoing efforts to strengthen preventive healthcare and reduce the burden of seasonal influenza continue to support the segment's substantial market presence.

The live attenuated segment is the fastest-growing vaccine type segment, driven by growing interest in alternative vaccine formulations and delivery approaches. Its appeal is supported by the potential for needle-free administration in suitable populations, which can improve convenience and acceptance for some recipients. Increasing emphasis on expanding vaccination coverage, along with continued research into vaccine technologies and more accessible immunization strategies, is expected to support the segment's growth.

Indication Segment Analysis: Quadrivalent (Largest & Fastest-Growing Segment)

The quadrivalent segment dominated the influenza vaccines market with an 82.43% share in 2026 and was also the fastest-growing indication segment. Its strong position is driven by the broad protection offered through coverage against multiple influenza strains, making it a key component of contemporary seasonal vaccination strategies. Growing efforts to improve population-level influenza prevention, rising awareness of vaccination benefits, and the continued emphasis on reducing the impact of seasonal outbreaks are supporting demand. The segment's alignment with evolving immunization practices and healthcare priorities further contributes to its combined leadership and growth momentum.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Vaccine Type	Inactivated, Live Attenuated	Inactivated	Live Attenuated
Indication	Quadrivalent, Trivalent	Quadrivalent	Quadrivalent
Age Group	Pediatric, Adult	Adult	Pediatric
Route of Administration	Injection, Nasal Spray	Injection	Nasal Spray
Distribution Channel	Hospitals & Pharmacies, Government & Institutional Supply, Other	Hospitals & Pharmacies	Government & Institutional Supply

Competitive Landscape and Market Positioning

Leading companies in the influenza vaccines market:

1. Sanofi S.A. (France)

2. GSK plc (United Kingdom)

3. CSL Limited (Australia)

4. AstraZeneca plc (United Kingdom)

5. Pfizer Inc. (United States)

6. Seqirus Ltd. (United Kingdom)

7. Moderna Inc. (United States)

8. Merck & Co. Inc. (United States)

9. Sinovac Biotech Ltd. (China)

10. Viatris Inc. (United States)

The influenza vaccines market is evolving through continuous advancements in vaccine technologies, including cell-based production and next-generation immunization platforms. Manufacturers are strengthening research capabilities to improve vaccine effectiveness and accelerate response to seasonal virus mutations. Investments in scalable production technologies and distribution efficiency are also becoming critical competitive priorities within the influenza vaccines market.

Industry Development/News

Company Name	Date	Key Development
Merck	Nov-25	Merck entered a definitive agreement to acquire Cidara Therapeutics' long-acting influenza prophylactic candidate, CD388, for approximately $9.2 billion. Currently in Phase 3 development, the asset is positioned to provide prophylactic coverage for high-risk populations, representing a significant strategic investment in the influenza prevention landscape.
CSL Seqirus	Dec-25	CSL Seqirus inaugurated a $1 billion manufacturing facility in Melbourne. This major infrastructure investment is dedicated to the production of cell-based influenza vaccines and antivenoms, substantially increasing regional manufacturing capacity and enhancing the resilience of the global influenza vaccine supply chain.
Sanofi	May-24	Sanofi finalized a strategic partnership with Novavax, involving a $500 million upfront payment to co-commercialize the Novavax COVID-19 vaccine and collaborate on the development of future combination influenza-COVID-19 vaccine candidates utilizing Novavax’s Matrix-M adjuvant technology.
Sanofi	Jan-26	Sanofi discontinued its mRNA seasonal influenza vaccine program. The company remains committed to the influenza market, shifting its strategic focus toward the continued clinical development of an mRNA-based H5 influenza vaccine candidate specifically tailored for pandemic preparedness.
Moderna	Dec-25	Moderna secured up to $54 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the Phase 3 clinical development of its mRNA-based pandemic influenza vaccine candidate, bolstering global efforts to prepare against potential avian influenza outbreaks.
CSL Seqirus	Sep-24	CSL Seqirus was awarded a $121.4 million contract by BARDA to supply adjuvant material sufficient for approximately 40 million pandemic influenza vaccine doses. This procurement strengthens the U.S. government’s strategic stockpile and regional preparedness efforts against potential pandemic-level influenza threats.
AstraZeneca	Jan-25	AstraZeneca cancelled a planned £450 million expansion of its vaccine manufacturing facility in Liverpool. The decision followed a reduction in projected government funding, resulting in the termination of planned production capacity increases for its vaccine portfolio.
Pan American Health Organization (PAHO)	May-26	PAHO reached a regional supply agreement to reserve pandemic influenza vaccine doses for countries across Latin America and the Caribbean. This strategic collaboration enhances regional vaccine distribution logistics and strengthens collective pandemic preparedness frameworks for the Latin American market.
Moderna	Mar-26	Moderna achieved a regulatory milestone as the European Medicines Agency provided support for its combined influenza-COVID mRNA vaccine candidate. This advancement signals progress in the commercialization of next-generation, high-efficacy respiratory vaccines in Europe.
European Commission	Feb-26	The European Commission launched a €225 million pre-commercial procurement initiative focused on developing next-generation influenza vaccines. The program aims to accelerate innovation in vaccine technologies capable of providing broader protection and facilitating faster manufacturing response times to emerging pandemic strains.